Your browser is no longer supported. Please, upgrade your browser.
United Therapeutics Corporation
Index- P/E20.11 EPS (ttm)9.05 Insider Own0.20% Shs Outstand44.60M Perf Week-1.43%
Market Cap8.25B Forward P/E12.08 EPS next Y15.06 Insider Trans-6.60% Shs Float43.82M Perf Month1.40%
Income405.40M PEG13.41 EPS next Q3.02 Inst Own99.70% Short Float3.83% Perf Quarter-9.74%
Sales1.51B P/S5.48 EPS this Y583.80% Inst Trans0.17% Short Ratio5.46 Perf Half Y11.05%
Book/sh77.25 P/B2.36 EPS next Y40.36% ROA9.10% Target Price214.56 Perf Year60.29%
Cash/sh38.17 P/C4.77 EPS next 5Y1.50% ROE12.30% 52W Range98.37 - 212.62 Perf YTD19.86%
Dividend- P/FCF14.38 EPS past 5Y-1.90% ROI10.90% 52W High-14.43% Beta0.47
Dividend %- Quick Ratio6.40 Sales past 5Y0.20% Gross Margin92.80% 52W Low84.94% ATR4.43
Employees950 Current Ratio6.70 Sales Q/Q6.40% Oper. Margin23.80% RSI (14)46.52 Volatility2.22% 2.35%
OptionableYes Debt/Eq0.00 EPS Q/Q-80.50% Profit Margin26.90% Rel Volume0.67 Prev Close184.22
ShortableYes LT Debt/Eq0.23 EarningsAug 04 BMO Payout0.00% Avg Volume307.36K Price181.93
Recom2.10 SMA20-1.53% SMA50-0.08% SMA2008.83% Volume206,178 Change-1.24%
Jul-14-21Upgrade Argus Hold → Buy $205
Apr-26-21Resumed Credit Suisse Outperform $196
Feb-01-21Upgrade H.C. Wainwright Neutral → Buy $125 → $195
Sep-14-20Resumed JP Morgan Overweight $142
Jun-25-20Reiterated H.C. Wainwright Neutral $85 → $125
Mar-10-20Upgrade Jefferies Hold → Buy $123
Feb-27-20Upgrade Cowen Market Perform → Outperform $119 → $145
Jan-31-20Upgrade JP Morgan Neutral → Overweight $120
Dec-03-19Initiated BofA/Merrill Underperform
Aug-01-19Upgrade Ladenburg Thalmann Neutral → Buy $103 → $106
Aug-01-19Upgrade Jefferies Underperform → Hold $90
Jul-01-19Upgrade Credit Suisse Neutral → Outperform $98 → $101
May-17-19Upgrade UBS Sell → Neutral $115 → $94
May-09-19Upgrade Credit Suisse Underperform → Neutral $98
Oct-12-18Upgrade Standpoint Research Hold → Buy
Aug-08-18Downgrade Credit Suisse Neutral → Underperform
Apr-03-18Upgrade Credit Suisse Underperform → Neutral
Feb-22-18Reiterated Barclays Underweight $115 → $105
Jan-18-18Resumed Credit Suisse Underperform $118
Dec-27-17Reiterated Wedbush Outperform $213 → $232
Jul-29-21 08:16AM  
Jul-28-21 03:03PM  
Jul-21-21 10:06AM  
Jun-30-21 06:00AM  
Jun-23-21 01:12PM  
Jun-17-21 09:40AM  
Jun-16-21 10:59AM  
Jun-14-21 10:01AM  
Jun-07-21 06:00AM  
Jun-04-21 11:31AM  
Jun-03-21 06:00AM  
May-25-21 06:00AM  
May-06-21 09:32AM  
May-05-21 03:01PM  
Apr-28-21 12:34PM  
Apr-26-21 10:20AM  
Apr-19-21 06:00AM  
Apr-06-21 03:16PM  
Apr-05-21 08:13AM  
Apr-02-21 07:07AM  
Apr-01-21 08:25AM  
Mar-26-21 11:31AM  
Mar-24-21 06:00AM  
Mar-09-21 06:00AM  
Mar-03-21 11:05AM  
Feb-27-21 03:05AM  
Feb-25-21 02:30PM  
Feb-24-21 04:30PM  
Feb-18-21 05:20AM  
Feb-17-21 06:00AM  
Feb-10-21 06:00AM  
Jan-28-21 04:51PM  
Jan-27-21 04:13PM  
Jan-21-21 11:00PM  
Jan-20-21 10:30AM  
Jan-13-21 05:01PM  
Jan-07-21 09:28AM  
Jan-04-21 06:00AM  
Dec-28-20 09:00AM  
Dec-20-20 07:03PM  
Dec-15-20 04:13PM  
Dec-09-20 06:00AM  
Nov-27-20 11:31AM  
Nov-26-20 09:14AM  
Nov-24-20 06:00AM  
Nov-10-20 06:00AM  
Nov-05-20 01:20PM  
Nov-02-20 05:55AM  
Oct-28-20 02:31PM  
Oct-27-20 11:59AM  
Oct-22-20 06:00AM  
Oct-21-20 06:00AM  
Oct-15-20 06:00AM  
Sep-21-20 07:00AM  
Sep-17-20 01:01PM  
Sep-16-20 06:00AM  
Sep-11-20 06:00AM  
Sep-09-20 10:43AM  
Aug-28-20 11:31AM  
Aug-18-20 11:13AM  
Aug-17-20 07:31AM  
Aug-05-20 06:00AM  
Jul-30-20 07:32PM  
Jul-29-20 08:02PM  
Jul-23-20 06:00AM  
Jul-22-20 12:32PM  
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAHON PAUL AEVP & General CounselJul 15Option Exercise94.966,000569,76042,369Jul 16 04:31 PM
MAHON PAUL AEVP & General CounselJul 01Option Exercise94.966,000569,76042,369Jul 02 04:31 PM
KURZWEIL RAYDirectorJun 26Option Exercise0.001,68009,220Jun 28 06:54 PM
SULLIVAN LOUIS WDirectorJun 26Option Exercise0.001,680011,100Jun 28 06:17 PM
Klein Katherine JDirectorJun 26Option Exercise0.001,68001,680Jun 28 06:14 PM
Mesa NildaDirectorJun 26Option Exercise0.001,68001,680Jun 29 04:40 PM
Thompson Tommy GDirectorJun 26Option Exercise0.001,68006,520Jun 29 04:39 PM
PATUSKY CHRISTOPHERDirectorJun 26Option Exercise0.001,68003,980Jun 29 04:36 PM
DWEK RAYMONDDirectorJun 26Option Exercise0.003,36003,360Jun 29 04:34 PM
Olian Judy D.DirectorJun 26Option Exercise0.003,36009,150Jun 29 04:33 PM
Giltner RichardDirectorJun 26Option Exercise0.003,360011,710Jun 29 04:31 PM
MAHON PAUL AEVP & General CounselJun 17Option Exercise94.966,000569,76042,369Jun 21 04:32 PM
MAHON PAUL AEVP & General CounselJun 03Option Exercise94.966,000569,76042,369Jun 04 04:32 PM
MAHON PAUL AEVP & General CounselMay 20Option Exercise94.966,000569,76042,369May 24 04:33 PM
SULLIVAN LOUIS WDirectorMay 11Option Exercise75.9730,0002,278,95024,420May 12 04:34 PM
PATUSKY CHRISTOPHERDirectorMay 10Sale190.5210019,0521,200May 10 04:31 PM
MAHON PAUL AEVP & General CounselMay 06Option Exercise94.966,000569,76042,369May 10 04:32 PM
PATUSKY CHRISTOPHERDirectorMay 06Option Exercise63.902,500159,7504,800May 10 04:31 PM
DWEK RAYMONDDirectorMay 05Option Exercise54.772,000109,5402,000May 06 04:40 PM
DWEK RAYMONDDirectorApr 28Option Exercise54.772,000109,5402,000Apr 29 04:32 PM
DWEK RAYMONDDirectorApr 21Option Exercise54.772,000109,5402,000Apr 22 04:31 PM
MAHON PAUL AEVP & General CounselApr 15Option Exercise94.966,000569,76042,369Apr 16 04:33 PM
DWEK RAYMONDDirectorApr 14Option Exercise54.772,000109,5402,000Apr 15 04:32 PM
DWEK RAYMONDDirectorApr 07Option Exercise54.772,000109,5402,000Apr 08 05:26 PM
Olian Judy D.DirectorApr 01Option Exercise76.364,207321,2479,997Apr 02 09:33 AM
MAHON PAUL AEVP & General CounselApr 01Option Exercise94.966,000569,76042,369Apr 02 09:35 AM
Olian Judy D.DirectorApr 01Sale184.964,207778,1275,790Apr 02 09:33 AM
KURZWEIL RAYDirectorMar 26Option Exercise54.773,750205,38811,290Mar 29 04:31 PM
MAHON PAUL AEVP & General CounselMar 18Option Exercise94.966,000569,76042,369Mar 19 04:32 PM
Olian Judy D.DirectorMar 17Option Exercise76.362,103160,5857,893Mar 19 04:32 PM
Olian Judy D.DirectorMar 17Sale170.002,103357,5105,790Mar 19 04:32 PM
Thompson Tommy GDirectorMar 10Option Exercise54.7712,350676,41017,190Mar 11 04:35 PM
MAHON PAUL AEVP & General CounselMar 04Option Exercise94.966,000569,76042,369Mar 05 05:26 PM
MAHON PAUL AEVP & General CounselFeb 18Option Exercise94.966,000569,76042,131Feb 19 04:33 PM
MAHON PAUL AEVP & General CounselFeb 04Option Exercise94.966,000569,76042,131Feb 05 04:31 PM
MAHON PAUL AEVP & General CounselJan 21Option Exercise94.966,000569,76042,131Jan 22 04:31 PM
CAUSEY CHRISTOPHERDirectorJan 15Option Exercise88.031,500132,0452,325Jan 19 04:39 PM
MAHON PAUL AEVP & General CounselJan 07Option Exercise94.966,000569,76042,131Jan 08 04:39 PM
CAUSEY CHRISTOPHERDirectorJan 07Option Exercise88.031,500132,0452,325Jan 08 04:38 PM
CAUSEY CHRISTOPHERDirectorJan 06Option Exercise88.031,500132,0452,325Jan 08 04:38 PM
Giltner RichardDirectorJan 06Option Exercise48.1110,000481,10018,350Jan 08 04:36 PM
Giltner RichardDirectorJan 05Option Exercise48.115,000240,55013,350Jan 06 04:35 PM
CAUSEY CHRISTOPHERDirectorJan 05Option Exercise88.031,500132,0452,325Jan 06 04:31 PM
Giltner RichardDirectorJan 04Option Exercise54.775,000273,85013,350Apr 16 04:32 PM
CAUSEY CHRISTOPHERDirectorDec 31Option Exercise88.037,500660,2258,325Jan 04 04:30 PM
CAUSEY CHRISTOPHERDirectorDec 23Option Exercise88.031,500132,0452,325Dec 28 04:32 PM
MAHON PAUL AEVP & General CounselDec 17Option Exercise94.966,000569,76042,131Dec 18 04:58 PM
Giltner RichardDirectorDec 17Option Exercise54.775,000273,85013,350Dec 18 04:56 PM
PATUSKY CHRISTOPHERDirectorDec 08Option Exercise63.903,000191,7005,300Dec 09 04:31 PM
MAHON PAUL AEVP & General CounselDec 03Option Exercise94.966,000569,76042,131Dec 04 04:51 PM
DWEK RAYMONDDirectorNov 10Option Exercise48.112,00096,2202,000Nov 12 04:33 PM
MAHON PAUL AEVP & General CounselNov 05Option Exercise94.966,000569,76042,131Nov 06 04:31 PM
Giltner RichardDirectorNov 04Option Exercise54.775,000273,85013,350Nov 05 04:33 PM
DWEK RAYMONDDirectorNov 02Option Exercise54.775,000273,8505,000Nov 03 04:44 PM
BENKOWITZ MICHAELPresident and COONov 02Option Exercise63.4228,2001,788,42023,748Nov 03 04:43 PM
CAUSEY CHRISTOPHERDirectorOct 28Option Exercise63.902,000127,8002,825Oct 29 04:32 PM
CAUSEY CHRISTOPHERDirectorOct 22Option Exercise63.902,500159,7503,325Oct 23 04:32 PM
CAUSEY CHRISTOPHERDirectorOct 16Option Exercise63.902,250143,7752,325Oct 19 04:33 PM
PATUSKY CHRISTOPHERDirectorAug 05Option Exercise54.775,000273,8507,300Aug 06 06:13 PM